The best time to get into a SPAC is before a business combination announcement. But how do you know which one is the best? We explain four key considerations you need to take to find the best SPACs before they shoot up in value. We've leveraged these tactics to make 100%+ returns by getting into SPACs before they get noticed. Here are some videos to help you with SPACs! - SPACs 101: https://youtu.be/U9tXrMxp4Uc - PSTH SPAC: https://youtu.be/-HsTnRJRVGs ► Website (Check us out!): https://www.wx.capital/ ► Facebook: https://www.facebook.com/WXCapitalUS/ ► Instagram: https://www.instagram.com/wx.capital/ ► Twitter: https://twitter.com/WXCapital ► Linkedin: https://www.linkedin.com/company/wxca... ► Seeking Alpha: https://seekingalpha.com/user/48516256/ ► Stocktwits: https://stocktwits.com/WX_Capital ► Demystifying Biotech Series: https://www.youtube.com/playlist?list=PLFWAjjtIlaxrS4MIUcczDtA8a-21aiqnml ------------------------------------------------------------------------------------------------------------------------- Who we are: WX Capital is led by ex-life science consultants and ex-bankers who have attained over 35% annually by investing in biotech stocks. We've decided to share our biotech expertise through our affordable subscription service, where members receive real-time stock trades, market updates, and exclusive access to stock diligence. Join today and get a leg up in the market! Sign-up today for our free weekly newsletter on market trends and stock performance. Or try out a free trial to experience everything we offer! ► Join Here: https://www.wx.capital/subscribe DISCLAIMER: This content is strictly for educational purposes, and should not be taken as financial and or investment advice. The publisher of this video assumes no responsibility for your trading performance as a result of watching one of these videos. #SPACs #DKNG #SPACTips

Find out why Mirati Therapeutics (MRTX) grew 50% year to date. Is MRTX a good company? How are they positioned for the future? We talk about all of this in our discussion with Breaking Biotech. Special thanks to Matt to having this discussion with us! Breaking Biotech's Website: https://breakingbiotech.com/ Breaking Biotech's YT Channel: https://www.youtube.com/channel/UCRAYTVPWxtd-uybPTSeITfw ► Website (Check us out!): https://www.wx.capital/ ► Facebook: https://www.facebook.com/WXCapitalUS/ ► Instagram: https://www.instagram.com/wx.capital/ ► Twitter: https://twitter.com/WXCapital ► Linkedin: https://www.linkedin.com/company/wxca... ► Seeking Alpha: https://seekingalpha.com/user/48516256/ ► Stocktwits: https://stocktwits.com/WX_Capital ► Demystifying Biotech Series: https://www.youtube.com/playlist?list=PLFWAjjtIlaxrS4MIUcczDtA8a-21aiqnml ------------------------------------------------------------------------------------------------------------------------- Who we are: WX Capital is led by ex-life science consultants and ex-bankers who have attained over 35% annually by investing in biotech stocks. We've decided to share our biotech expertise through our affordable subscription service, where members receive real-time stock trades, market updates, and exclusive access to stock diligence. Join today and get a leg up in the market! Sign-up today for our free weekly newsletter on market trends and stock performance. Or try out a free trial to experience everything we offer! ► Join Here: https://www.wx.capital/subscribe DISCLAIMER: This content is strictly for educational purposes, and should not be taken as financial and or investment advice. The publisher of this video assumes no responsibility for your trading performance as a result of watching one of these videos. #MRTX #BiotechResearch #BreakingBiotech

Tesla stock share price increased by ~500% since COVID first hit. This is due to several factors. The first factor is low interest rates. The second factor is an influx in retail investors. Finally, the third factor is the focus on total addressable market size (TAM) rather than value investing. If the number of retail investors maintains after COVID, we may be in a new era of investing, focused more on individual industry-disrupting companies with large TAM that have yet to demonstrate significant revenue, profits, and cash flow. ► Website (Check us out!): https://www.wx.capital/ ► Facebook: https://www.facebook.com/WXCapitalUS/ ► Instagram: https://www.instagram.com/wx.capital/ ► Twitter: https://twitter.com/WXCapital ► Linkedin: https://www.linkedin.com/company/wxca... ► Seeking Alpha: https://seekingalpha.com/user/48516256/ ► Stocktwits: https://stocktwits.com/WX_Capital ► Demystifying Biotech Series: https://www.youtube.com/playlist?list=PLFWAjjtIlaxrS4MIUcczDtA8a-21aiqnml ------------------------------------------------------------------------------------------------------------------------- Who we are: WX Capital is led by ex-life science consultants and ex-bankers who have attained over 35% annually by investing in biotech stocks. We've decided to share our biotech expertise through our affordable subscription service, where members receive real-time stock trades, market updates, and exclusive access to stock diligence. Join today and get a leg up in the market! Sign-up today for our free weekly newsletter on market trends and stock performance. Or try out a free trial to experience everything we offer! ► Join Here: https://www.wx.capital/subscribe DISCLAIMER: This content is strictly for educational purposes, and should not be taken as financial and or investment advice. The publisher of this video assumes no responsibility for your trading performance as a result of watching one of these videos. #TAM #TAMInvesting #ValueInvesting

When taking a look at the history of a biotech stock's valuation, you may have noticed certain inflection points that drastically impacted stock price, especially for smaller companies. What is driving these inflection points? And when thinking of investing in a biotech stock, what should you be looking out for that could impact the price? Today, we would like to hone in on a unique aspect of this industry - clinical trial readouts, and what they mean for investors. We will take you through each step of the clinical trial process, and what to watch out for when making investment decisions. Any additional questions? Any specific topics you would like for us to profile? Please leave a comment below. Structure: Preface (Preclinical Trials) Phase 1 Trials Phase 2 Trials Phase 3 Trials Conclusion ► Website (Check us out!): https://www.wx.capital/ ► Facebook: https://www.facebook.com/WXCapitalUS/ ► Instagram: https://www.instagram.com/wx.capital/ ► Twitter: https://twitter.com/WXCapital ► Linkedin: https://www.linkedin.com/company/wxca... ► Seeking Alpha: https://seekingalpha.com/user/48516256/ ► Stocktwits: https://stocktwits.com/WX_Capital ► Demystifying Biotech Series: https://www.youtube.com/playlist?list=PLFWAjjtIlaxrS4MIUcczDtA8a-21aiqnml The video also touches upon FDA designations and PDUFA dates. Here's a summary of what I learned and what might be helpful for you. Preclinical Trials: these trials don't impact a company's evaluation that much because results from animals don't always translate to results from humans. Phase 1 Trials: generally, there isn't much upside in this phase. That's because if the results are positive, it still needs to pass the other phases and thus stays in the status quo. If they're negative, you might be able to expect a negative evaluation of the company and it's stock. However, if the results are positive in patients and for a hard-to-treat disease, you can expect an upside for investors. Phase 2 Trials: These almost always have human patients. Furthermore, these trials are the most difficult barrier to get by so positive results will clear a major hurdle. These trials will have a large effect on a company's evaluation. Phase 3 Trials: These trials are the single biggest driver for a company's stock price. If they get past this stage, these companies get assigned a PDUFA date and have the potential to get their drugs approved and on the market. ------------------------------------------------------------------------------------------------------------------------- Who we are: WX Capital is led by ex-life science consultants and ex-bankers who have attained over 35% annually by investing in biotech stocks. We've decided to share our biotech expertise through our affordable subscription service, where members receive real-time stock trades, market updates, and exclusive access to stock diligence. Join today and get a leg up in the market! Sign-up today for our free weekly newsletter on market trends and stock performance. Or try out a free trial to experience everything we offer! ► Join Here: https://www.wx.capital/subscribe DISCLAIMER: This content is strictly for educational purposes, and should not be taken as financial and or investment advice. The publisher of this video assumes no responsibility for your trading performance as a result of watching one of these videos. #DemystifyingBiotech #ClinicalTrials #InvestingTips

The world is currently racing for a vaccine to the COVID-19 virus. There are over 25 companies with vaccines in clinical trials. So who is going to get there first, and does first to the finish line mean first place in the vaccine race? In this video, WX Capital takes a look at this race and analyzes the companies in this collaborative battle. We found the 5 most likely companies to succeed in this race and take a deep look at their positions in this race and the development of their COVID vaccines. From a company with a COVID vaccine already in use by humans to companies with COVID vaccines in phase 3 of development, everything is considered. The Top 5 Leading Companies in the Race for the COVID Vaccine: Honorable Mention - GSK & SANOFI 5) CanSino Biologics 4) Johnson & Johnson 3) Moderna 2) Pfizer 1) AstraZeneca EDIT: 2:12 - A Russian COVID Vaccine was approved ► Website (Check us out!): https://www.wx.capital/ ► See our RESEARCH: https://www.wx.capital/public-research ► Facebook: https://www.facebook.com/WXCapitalUS/ ► Instagram: https://www.instagram.com/wx.capital/ ► Twitter: https://twitter.com/WXCapital ► Linkedin: https://www.linkedin.com/company/wxca... 1: AstraZeneca/Oxford (CHAD-OX1): - Using CHAD-OX1 based on Oxford technology. Weakened version of an adenovirus that infects chimps, so most people shouldn't be resistant. - First to start phase 3 trials, announcing on June 27th that a 5 K participant trial in Brazil had begun, Results may be ready in August/September. - Lent vaccine production capabilities from Catalent. They are the farthest along in terms of lining up the manufacturing capabilities, as they have orchestrated a network of more than 20 contract manufacturers to rapidly create 2 billion doses. 2: Pfizer (BNT162b2): - Co-dev. With German mRNA company BioNTech, in Phase I/II - Just announced they are starting phase 2/3 trials with 30 K participants and 120 sites globally. - Had four shots on goal in phase 1/2, with different versions of the bits of COVID that are needed to generate an immune response. - They are aiming to gain regulatory approval by this October, with 100 M doses by the end of 2020 and 1.3 B by end of 2021. - Already has a deal with the U.S. govt for 50 M innoculations at a price of $2 B. It has also signed deals with UK and Japan 3: Moderna (MRNA-1273): - Moderna's specialty in mRNA allowed them to get on COVID vaccine quick, and they came out as the early leader in the vaccine race by starting trials in mid march. - They blew through the development, starting a phase 2 in mid may and now Starting large-scale phase 3 trial in July of 30 K people. Stock has tripled since they got into the race. Even got a shoutout from Mike Pence about starting their phase 3. - However, executives in the company have been selling off their shares at an alarming rate, which has cast some doubt over their own confidence in their vaccine. 4: J&J (Ad26.COV2.S): - Uses an adenovirus vector to deliver a gene for coronavirus antigen into cells - Phase 1 going on in Belgium and the U.S. - Published results in the prestigious Nature showing a single dose provided complete or near-complete protection in monkeys. This one is special because it only requires one dose. - Blazing through the trials, they are aiming to start a Phase III in September. - Signed a deal with the U.S. govt to 100 M doses for $1 B 5: CanSino: - Major China player. - Adenovirus-based vector was used for Ebola vaccines. - Jointly developed by Institute of Biotech as part of Academy of Military Medical Sciences. - About to start Phase III trials, and is already approved by the Chinese government to be used for military personnel. - The virus delivers a protein used by COVID to immune cells called antigen presenting cells, which activates a T cell response. - One issue is using AAV5, which many people are already immune to. Currently, has manufacturing capacity to produce 100 M/yr. ------------------------------------------------------------------------------------------------------------------------- Who we are: WX Capital is led by ex-life science consultants and ex-bankers who have attained over 35% annually by investing in biotech stocks. We've decided to share our biotech expertise through our affordable subscription service, where members receive real-time stock trades, market updates, and exclusive access to stock diligence. Join today and get a leg up in the market! Sign-up today for our free weekly newsletter on market trends and stock performance. Or try out a free trial to experience everything we offer! ► Join Here: https://www.wx.capital/subscribe DISCLAIMER: This content is strictly for educational purposes, and should not be taken as financial and or investment advice. The publisher of this video assumes no responsibility for your trading performance as a result of watching one of these videos. #Moderna #AstraZeneca #COVIDVaccine

In this video, I discuss the core aspects that go into investing in BIOTECH. Since biotech is significantly different than other types of companies, it requires unorthodox or different strategies from the norm of investing. We're trying to show you how you can take advantage of these differences with these styles of investing. As a bonus, I also talk about what my personal preference is when it comes to biotech investing. From these tips, you should have a better grasp of how and what it is like when investing in biotech. You should understand how much time it takes to get returns, what causes market changes, and the potential that can come from biotech stocks. The four aspects that go into biotech investing: 1) Time Horizon 2) Market Cap 3) Equities versus Options 4) Value versus Catalyst Investing ► Website (Check us out!): https://www.wx.capital/ ► See our RESEARCH: https://www.wx.capital/public-research ► Facebook: https://www.facebook.com/WXCapitalUS/ ► Instagram: https://www.instagram.com/wx.capital/ ► Twitter: https://twitter.com/WXCapital ► Linkedin: https://www.linkedin.com/company/wxca... ► Demystifying Biotech Series: https://www.youtube.com/playlist?list=PLFWAjjtIlaxrS4MIUcczDtA8a-21aiqnm ------------------------------------------------------------------------------------------------------------------------- Who we are: WX Capital is led by ex-life science consultants and ex-bankers who have attained over 35% annually by investing in biotech stocks. We've decided to share our biotech expertise through our affordable subscription service, where members receive real-time stock trades, market updates, and exclusive access to stock diligence. Join today and get a leg up in the market! Sign-up today for our free weekly newsletter on market trends and stock performance. Or try out a free trial to experience everything we offer! ► Join Here: https://www.wx.capital/subscribe DISCLAIMER: This content is strictly for educational purposes, and should not be taken as financial and or investment advice. The publisher of this video assumes no responsibility for your trading performance as a result of watching one of these videos. #Biotech #BiotechInvesting #LearnInvesting

We've created a video that explains how vaccines work and how vaccines would work in relation to the COVID-19 virus. We talk about the vaccine history and the types of vaccines that exist. We also go over Moderna's potential vaccine and discuss how its vaccine works. Here's what we dive into: 1: Live-attenuated Vaccines 2: Inactivated Vaccines 3: Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines 4: Viral Vector Vaccine 5.0: mRNA Vaccine 5.5: mRNA Vaccine ► Website (Check us out!): https://www.wx.capital/ ► See our RESEARCH: https://www.wx.capital/public-research ► Facebook: https://www.facebook.com/WXCapitalUS/ ► Instagram: https://www.instagram.com/wx.capital/ ► Twitter: https://twitter.com/WXCapital ► Linkedin: https://www.linkedin.com/company/wxca... ► Demystifying Biotech Series: https://www.youtube.com/playlist?list=PLFWAjjtIlaxrS4MIUcczDtA8a-21aiqnm ------------------------------------------------------------------------------------------------------------------------- Who we are: WX Capital is led by ex-life science consultants and ex-bankers who have attained over 35% annually by investing in biotech stocks. We've decided to share our biotech expertise through our affordable subscription service, where members receive real-time stock trades, market updates, and exclusive access to stock diligence. Join today and get a leg up in the market! Sign-up today for our free weekly newsletter on market trends and stock performance. Or try out a free trial to experience everything we offer! ► Join Here: https://www.wx.capital/subscribe DISCLAIMER: This content is strictly for educational purposes, and should not be taken as financial and or investment advice. The publisher of this video assumes no responsibility for your trading performance as a result of watching one of these videos. #WXCapital #COVIDVaccine #COVIDInvesting

Last Friday, President Trump signed three executive orders and threatened pharma with a fourth to decrease the price of drugs. The signed executive orders include 1) providing insulin at 1 cent per unit 2) increase drug importation and 3) eliminating rebates to pharmacy benefit managers (PBMs). The potential fourth order may involve international price referencing, which would have the greatest impact on biopharma companies. If implemented, these orders will benefit U.S. patients’ wallets while negatively impact biopharma’s future revenues. However, it is important to consider the degree of impact these orders will have on different sectors and types of biopharma companies. Many policy experts do not think these orders are substantial as many of them are old and have yet to bear fruit. ► Article: https://www.wx.capital/post/how-will-president-trump-s-executive-orders-on-drug-pricing-impact-pharma-and-biotech-stocks ► Website (Check us out!): https://www.wx.capital/ ► See our RESEARCH: https://www.wx.capital/public-research ► Facebook: https://www.facebook.com/WXCapitalUS/ ► Instagram: https://www.instagram.com/wx.capital/ ► Twitter: https://twitter.com/WXCapital ► Linkedin: https://www.linkedin.com/company/wxca... ► Demystifying Biotech Series: https://www.youtube.com/playlist?list=PLFWAjjtIlaxrS4MIUcczDtA8a-21aiqnm Order 1: Providing insulin at 1 cent per unit will not greatly impact biopharma stocks given it is highly targeted towards one drug. The first order aimed at providing insulin at pennies per unit to assist the ~8M Americans who depend on insulin to manage their diabetes. This order will greatly impact the pricing potential for companies developing drugs to limit or reduce the use of insulin, such as Provention Bio ($PRVB). However, this targeted order will not greatly impact future revenues of biopharma players developing drugs outside of diabetes. Order 2: Increasing drug importation will negatively impact companies that sell drugs at a premium in the U.S. while others sell the same drug cheaper overseas. The second order aims to increase the importation of drugs from Canada by reducing trade barriers. This order targets companies that manufacture and sell drugs at a premium in the U.S. while companies overseas that sell the same drug for much cheaper. However, this will not impact companies that manufacture within the U.S. and sell the drug abroad for cheaper, unless the Trump administration implements re-importation measures like they did for insulin. Order 3: Eliminating rebates on PBMs target the middlemen and will likely impact big pharma rather than early-stage biotech companies. The third order impacts PBMs, who often take rebates or “kickbacks” of up to 50% drug price discounts from biopharma companies who seek to get their drugs to patients. However, this discount is not often seen by the patients - Medicare patients often pay the full price of the drug. The third order aims to narrow the rebates received PBMs, driving more of the discounts to patients. Biopharma companies will continue to provide discounts, except, under this order, more patients will see the discounts. One nuance is that large pharma often use rebates to protect their franchises past when they lose patent exclusivity. If these rebates are capped, PBMs may be less incentivized to leverage their power to drive volume towards large pharma companies. Early-stage biotech companies are less likely to be impacted given they focus on highly innovative drugs which may not need significant rebates to begin with. Potential Order 4: International price referencing will mostly impact companies that already distribute drugs internationally, but may also limit future revenue potential for early-stage biotech companies. The fourth order is most impactful on biopharma companies. Pharma companies that distribute drugs internationally will likely be hit hardest given prices are already set abroad. ------------------------------------------------------------------------------------------------------------------------- Who we are: WX Capital is led by ex-life science consultants and ex-bankers who have attained over 35% annually by investing in biotech stocks. We've decided to share our biotech expertise through our affordable subscription service, where members receive real-time stock trades, market updates, and exclusive access to stock diligence. Join today and get a leg up in the market! Sign-up today for our free weekly newsletter on market trends and stock performance. Or try out a free trial to experience everything we offer! ► Join Here: https://www.wx.capital/subscribe DISCLAIMER: This content is strictly for educational purposes, and should not be taken as financial and or investment advice. The publisher of this video assumes no responsibility for your trading performance as a result of watching one of these videos. #WXCapital #ExecutiveOrders #BiotechNews